The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
In men with nonmetastatic castration-resistant prostate cancer, a PSA doubling time of less than 3 months vs 15 months or more increases the risk of metastasis, which in turn is associated with a large increase in healthcare utilization and costs.
Patients with localized prostate cancer characterized by high-risk features are at increased risk of a negative outcome following radical prostatectomy.
Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.
In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression.
Men in the highest tertile of high-sensitivity C-reactive protein level had a 30% increased risk for prostate cancer compared with those in the lowest tertile in adjusted analyses.
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review.
